SAN DIEGO , Sept. 29, 2016 /PRNewswire/ -- Biocept, Inc . ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that clinical results featuring
Clarient, Inc., a GE company, announces the launch of Biocept’s proprietary Circulating Tumor Cells (CTC) test for HER2 status in breast cancer patient San Diego and Aliso Viejo, California: – Biocept, Inc., a privately-held laboratory services company focused on Circulating Tumor Cells (CTCs), and
Letter to the editor highlights capability of Target Selector™ test to detect ROS1, a lung cancer biomarker used to qualify patients for targeted therapies that can improve treatment outcomes SAN DIEGO , May 1, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Expands global intellectual property portfolio for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and other genetic alterations of interest; increases Biocept's total patent awards for technologies used in molecular diagnostics to 39 SAN DIEGO , April 9,
SAN DIEGO --(BUSINESS WIRE)--Aug. 14, 2023-- Biocept, Inc . (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS
Spotlight Presentation at SABCS showed that in 38% of patients the HER2 status of the metastatic cancer differed from the primary tumor, offering new information to aid treatment decisions SAN DIEGO --(BUSINESS WIRE)--Dec. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case
Study to be presented at the Society for Neuro-Oncology Third Annual Conference on Brain Metastases, Aug. 19-20 SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s
SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 th Annual ROTH Conference,
SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for